PATENT CLAIM ANALYSIS

Application Number: 16007417
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "235800"]

Abstract:
Aminothiazole compounds of Formula (I) shown below and pharmaceutical compositions containing one of such compounds: Also disclosed are methods of inhibiting a tyrosine kinase and treating cancer associated with a tyrosine kinase with one of the aminothiazole compounds.

Claim (Index 24):
The method of  claim 23 , wherein the tyrosine kinase is FMS-like tyrosine kinase 3 (FLT3), FMS-like tyrosine kinase 4, vascular endothelial growth factor receptor (VEGFR), colony stimulating factor 1 receptor (CSF1R), platelet-derived growth factor receptor (PDGFR) A, PDGFR B, tyrosine-protein kinase Kit (c-KIT), c-Src (SRC), tyrosine-protein kinase Lyn (LYN) A, LYN B, rearranged during transfection tyrosine kinase (RET), lymphocyte-specific protein tyrosine kinase, Gardner-Rasheed feline sarcoma viral oncogene homolog, discoidin domain receptor 1, kinase insert domain receptor, B lymphocyte kinase, tyrosine-protein kinase Yes, Abelson murine leukemia viral oncogene homolog 1 (ABL1), tyrosine receptor kinase TRKA, TRKB, TRKC, ZAK/MLTK, IRAK4, RET V804L, RET Y791F, FLT3 D835Y, PDGFR A V561D, or ABL1 T315I.

Metadata:
- Claim Count in Document: 39.0
- Percentile: 94.0
- Lexical Diversity: 1.35484
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15419183', '15257926', '15861688', '14670421', '14670425']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7766297042321649
- 35 USC 102 Novelty (BERT): 0.5421702748682876
- Combined Prediction Score: 0.7531837612957772
- Mean Citation Score: 323.369304
- Max Citation Score: 366.57004
- Similarity Product: 203.42664492476464

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test